Ensuring Safety, Enhancing Efficacy
with TheraCIM (Nimotuzumab) for treatment of
various solid EGFR expressing cancer types.
What is TheraCIM® and how can it help your patients?
Nimotuzumab (TheraCIM® h-R3) is a humanized monoclonal antibody directed against human Epidermal Growth Factor Receptor (EGFR). EGFR signalling pathway is known to contribute to tumour proliferation, apoptosis resistance, angiogenesis, invasion and metastasis. TheraCIM® is designed to target cells with particularly high expression of EGFR, therefore it can selectively bind to cancer cells with limited effect on healthy cells.